GlassScriptPhysician profile
Joseph H Williams
NPI 1235159583
$27,911.69
in general payments reported to CMS, 2019-2025
37 companies · $4,838 in 2025
The $4,838 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,463 · 2020: $2,607 · 2021: $4,139 · 2022: $3,515 · 2023: $3,852 · 2024: $6,497 · 2025: $4,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $2,000 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,086.46 |
| Consulting Fee | $2,000.00 |
| Education | $100.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,041.50 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $2,958.96 | 2022-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $2,706.59 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $2,581.75 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $2,077.06 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $1,946.24 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,361.18 | 2020-2025 | Caplyta |
| Lundbeck LLC | $1,257.04 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $1,248.69 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $997.55 | 2019-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $882.47 | 2019-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $796.51 | 2022-2025 | Qelbree, Qelbree |
| Corium, LLC | $770.31 | 2022-2025 | Azstarys |
| Allergan, INC. | $642.73 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $496.45 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $392.17 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $351.66 | 2020-2025 | Rejoyn, Abilify Maintena, Abilify Asimtufii |
| Merck Sharp & Dohme LLC | $319.28 | 2019-2023 | Belsomra |
| Eisai INC. | $286.63 | 2020-2021 | |
| Adlon Therapeutics L.P. | $253.81 | 2019-2021 | |
| Bausch Health US, LLC | $232.89 | 2021-2023 | Wellbutrin, Aplenzin |
| Janssen Scientific Affairs, LLC | $183.37 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Ironshore Pharmaceuticals INC. | $179.03 | 2019-2023 | Jornay Pm |
| Tris Pharma INC | $160.88 | 2023-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $132.98 | 2022-2024 | Quviviq |
| Shire North American Group INC | $95.83 | 2019 | |
| Almatica Pharma LLC | $86.08 | 2021-2025 | Loreev Xr |
| Optinose US, INC. | $83.52 | 2023-2024 | |
| Vertical Pharmaceuticals, LLC | $71.99 | 2024-2025 | Relexxii |
| Neos Therapeutics, LP | $61.14 | 2023 | Adzenys Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $59.17 | 2024-2025 | Cobenfy |
| Tempus Ai, INC | $53.10 | 2024 | |
| Arbor Pharmaceuticals, INC. | $51.72 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.37 | 2025 | |
| Sage Therapeutics, LLC | $22.92 | 2024 | |
| Harmony Biosciences LLC | $21.91 | 2020 | |
| Noven Therapeutics, LLC | $17.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.